NEWSROOM

Healthcare

Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results

Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results

Aug 8, 2024

Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., August 8, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders, We are thrilled to report that we have successfully launched GraftAssureTM, which is our research-use-only assay that can detect...

ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS

ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS

Aug 8, 2024

Patents issued in mainland China protect the Company’s novel secreted Klotho protein and Its gene delivery system Recent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer’s Disease and other neurodegenerative diseases New York, NY, August 8, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a US-based biotechnology company focused on developing cell- and gene-based treatments to affect aging and age-related diseases, announces the...

REMSleep Holdings Inc. Issues Shareholder Letter

REMSleep Holdings Inc. Issues Shareholder Letter

Aug 6, 2024

Company Unveils Internal Corporate Goal of Capturing 10% of the CPAP Mask Market Within 24 Months CLEARWATER, Fla., August 6, 2024 - REMSleep Holdings, Inc. (OTCQB: RMSL), a leader in innovative sleep apnea products, published the following letter to shareholders. Dear REMSleep Shareholders and Interested Investors: Our company’s primary focus is two-fold. First, we are dedicated to providing high-quality products and experiences for CPAP therapy to support our customers and their families....

Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results

Oncocyte Announces August Investor Conferences Participation

Aug 5, 2024

IRVINE, Calif., August 5, 2024 — Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following investor conferences in August: 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference, August 12-13, 2024. Oncocyte management plans to host meetings with investors. Sidoti Micro-Cap Virtual Conference, August 14-15, 2024. The company is scheduled to present on Wednesday, August 14,...

BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Aug 5, 2024

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., August 5, 2024, — BioStem Technologies, Inc. (OTC: BSEM), a leading medtech company specializing in the development, manufacture, and commercialization of placental-derived allografts for advanced wound care, announced today that it will release its second quarter 2024 financial results after the market close on Monday, August 12, 2024. The company will also host a conference call and webcast at 4:30 PM ET to discuss the...

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Aug 1, 2024

PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 2,066,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.62 per share (or...

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

Aug 1, 2024

Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Aug 1, 2024 - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company will host a conference call and webcast on Thursday, August 8, 2024, at 5:00 p.m. Eastern Time to discuss its financial results and highlights. Interested parties...

REMSleep Holdings, Inc. Announces Distributor Request for DELTAWAVE Nasal Pillows System Samples

REMSleep Holdings, Inc. Announces Distributor Request for DELTAWAVE Nasal Pillows System Samples

Jul 24, 2024

Clearwater, FL, July 24, 2024 - REMSleep Holdings, Inc. (OTCQB: RMSL), a leader in innovative sleep apnea products, is thrilled to announce that a significant distributor in the CPAP industry has requested samples of its new nasal interface, the DELTAWAVE Nasal Pillows System. This request marks a pivotal step in REMSleep's mission to revolutionize sleep apnea treatment with cutting-edge technology and superior comfort. REMSleep is currently in the process of preparing the DELTAWAVE Nasal...

SinglePoint CEO Issues Update to Shareholders Highlighting Key Operational Milestones

SinglePoint CEO Issues Update to Shareholders Highlighting Key Operational Milestones

Jul 24, 2024

Revenue up 20% YoY as subsidiary Boston Solar continues to grow PHOENIX, Arizona, July 24, 2024 -- SinglePoint Inc. (CBOE: SING), a leading provider in the renewable energy sector, issues an update to shareholders from CEO Wil Ralston highlighting key operational milestones: Dear Follow Shareholders, The Company continues to refine and strengthen operations as reflected in our recently filed annual financial statement (10K) for the year ended December 31, 2023. In particular, management...

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

Jul 24, 2024

Jackson Center, PA July 24, 2024 – Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-AxTM nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. Dr. Russell Carr, the project's Principal Investigator, commented: “In the early stages of our Phase II studies, we focused on assessing the efficacy of our innovative Tri-AxTM nasal spray in...

REMSleep Holdings Inc. Issues Shareholder Letter

REMSleep Holdings Inc. Announces Strategic Marketing Plan for DELTAWAVE Nasal Pillows System

Jul 17, 2024

Clearwater, FL, July 17, 2024– REMSleep Holdings Inc. (OTCQB: RMSL), a pioneer in sleep apnea treatment solutions, is thrilled to announce a comprehensive marketing strategy for its revolutionary DELTAWAVE Nasal Pillows System. This strategic plan aims to significantly expand the market presence of DELTAWAVE by identifying and partnering with key distributors nationwide The DELTAWAVE Nasal Pillows System, designed with cutting-edge technology, offers an innovative solution for those suffering...

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix’s HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix’s HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Jul 15, 2024

NEW YORK, N.Y., July 15, 2024 – PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's (Nasdaq: SNGX) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte™ (synthetic hypericin) is a novel photodynamic therapy for the treatment of early-stage cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin’s lymphoma with no FDA-approved first-line treatments. Highlights from the Q&A:...

MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in “Take Advantage of the Moment” Episode

MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in “Take Advantage of the Moment” Episode

Jul 11, 2024

HOLLAND, Mich., July 11, 2024 – MedTech Gurus, a leading podcast focused on the forefront of medical technology, featured Oncocyte Corporation (NASDAQ: OCX) CEO Josh Riggs in its latest episode, "Take Advantage of the Moment." In this episode, Riggs highlights Oncocyte's innovative strategies in molecular diagnostic technology and the significant impact of this technology on patient care. Hosted by Tom Hickey, a partner at Excelerant Consulting and a seasoned expert in medical device...

BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers

BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers

Jul 10, 2024

POMPANO BEACH, FL, July 10, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that the IRB has approved a clinical study to evaluate AmnioWrap2™ (AW2) in diabetic foot ulcers (DFU), one of the company’s placental-derived allograft commercial products. Jason Matuszewski, CEO of BioStem, commented: “Diabetic foot ulcers are a...

American Shared Hospital Services Announces Signing of Joint Venture Agreement for Gamma Knife Facility in Guadalajara, Mexico

American Shared Hospital Services Announces Signing of Joint Venture Agreement for Gamma Knife Facility in Guadalajara, Mexico

Jul 9, 2024

JV will Establish Company’s 4th International Center SAN FRANCISCO, CA, July 9, 2024 ‒ American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that it has signed a joint venture agreement to partner in a Gamma Knife treatment facility in Guadalajara, Mexico. AMS has signed a Joint Venture (“JV”) agreement with Hospital San...

REMSleep Holdings Inc. Receives 510(K) Clearance on Product

REMSleep Holdings Inc. Receives 510(K) Clearance on Product

Jul 9, 2024

CLEARWATER, FL, July 9, 2024 - REMSleep Holdings, Inc. (OTCQB: RMSL) announces the company has been awarded 510(K) Clearance for the new Deltawave CPAP Pillows Interface mask. The company would like to share the following correspondence with its shareholders: Re: K233415Trade/Device Name: DELTAWAVE Nasal Pillows SystemRegulation Number: 21 CFR 868.5905Regulation Name: Noncontinuous Ventilator (IPPB)Regulatory Class: Class IIProduct Code: BZDDated: October 4, 2023Received: October 10, 2023 Dear...

ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene

ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene

Jun 27, 2024

Collaboration focuses on research and development of ANEW’s patented Klotho gene therapy in enhancing longevity and reducing age-related diseases ANEW’s mission is to deliver transformative protein, cell, and gene therapies in areas of high unmet medical needs, particularly targeting highly prevalent neurodegenerative diseases and age-related disorders NEW YORK, June, 27. 2024 -- ANEW MEDICAL, INC. (Nasdaq: WENA), a biopharmaceutical company specializing in the advancement of novel...

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

Jun 26, 2024

Study published in peer-reviewed journal finds BioStem’s products offer overall better treatment efficiency, and greater efficiency in general wound closure POMPANO BEACH, Fla., June 26, 2024 -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that an article validating its proprietary processing method and its placental allograft...

ANEW MEDICAL, INC. Secures Key Patent in Europe for HUMAN Klotho Gene RNA Slice Variant and Protein

ANEW MEDICAL, INC. Secures Key Patent in Europe for HUMAN Klotho Gene RNA Slice Variant and Protein

Jun 26, 2024

ANEW to explore therapeutics and specialty diagnostics utilizing the s-KL protein and will pursue other medical product development and commercial opportunities of interest Exclusive, worldwide intellectual property licensed from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Barcelona, Spain NEW YORK, June 26, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA) (“ANEW” or “the Company”) a biopharmaceutical company specializing in the advancement...

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

Oncocyte Appoints Andrea James as Chief Financial Officer

Jun 17, 2024

IRVINE, Calif., June 17, 2024 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer. “We are thrilled to welcome Andrea as we approach the inflection point of commercial launch,” Oncocyte CEO Josh Riggs said. “She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and building...

SS Innovations Designated “Outstanding Company” Finalist for Surgical Robotics Industry Awards 2024

SS Innovations Designated “Outstanding Company” Finalist for Surgical Robotics Industry Awards 2024

Jun 17, 2024

Annual awards celebrate the best of the surgical robotics industry Fort Lauderdale, FL., June 17, 2024 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, was recently selected as a finalist in the Surgical Robotics Industry Awards 2024 in the “Outstanding Company” category. The Company’s SSi Mantra Surgical...

SS Innovations Designated “Outstanding Company” Finalist for Surgical Robotics Industry Awards 2024

SS Innovations’ SSi Mantra Surgical Robotic System Approved for Use in Indonesia

Jun 11, 2024

Fort Lauderdale, FL., June 11, 2024 - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, today announced that its SSi Mantra Surgical Robotic System has received regulatory approval from the Indonesian Ministry of Health for clinical use in the Republic of Indonesia. With more than 279 million people,...

GK Financing LLC, a Subsidiary of American Shared Hospital Services, Announces Extension of Agreement with PeaceHealth Sacred Heart Medical Center at RiverBend

GK Financing LLC, a Subsidiary of American Shared Hospital Services, Announces Extension of Agreement with PeaceHealth Sacred Heart Medical Center at RiverBend

Jun 7, 2024

Extended 10-year Agreement to Upgrade Gamma Knife® Perfexion™ with Elekta Esprit San Francisco, CA, June 7, 2024 – GK Financing LLC (GKF), a subsidiary of American Shared Hospital Services (NYSE American: AMS), a leading provider of turnkey technology solutions for advanced radiosurgery and radiation oncology services, announced today that it has extended its current agreement with PeaceHealth Sacred Heart Medical Center at RiverBend in Springfield, Ore. The new agreement will see the center...

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

BioStem Technologies to Sponsor MRO Better Half Dash

May 29, 2024

POMPANO BEACH, Fla., May 29, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics, will sponsor the MRO Better Half Dash which will be held on May 29, 2024, from 4:00 PM – 9:00 PM at the Trackhouse Motorplex, 130 Motorplex Dr, Mooresville, NC. The Better Half Dash has become a beloved annual event in NASCAR, eagerly anticipated by fans and participants alike. Billy...

SS Innovations’ SSi Mantra Surgical Robotic System Used to Perform 100 Cardiac Surgeries, Signaling Market Expansion

SS Innovations’ SSi Mantra Surgical Robotic System Used to Perform 100 Cardiac Surgeries, Signaling Market Expansion

May 21, 2024

The SSi Mantra has surpassed the 100 surgery milestone for robotic cardiac surgery SS Innovations maintains the world's only comprehensive robotic cardiac surgery program SSi Mantra used in more than 1000 procedures globally Company anticipates FDA approval in early 2025 FORT LAUDERDALE, FL, May 21, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery...

Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

May 21, 2024

Share: Company to initiate Phase 2b clinical trial in lead asset, LP-10 in 2H 2024 Pittsburgh, PA, May 21, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug Administration (“FDA”) Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program. Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic...

American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on Tuesday, June 25, 2024

American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on Tuesday, June 25, 2024

May 21, 2024

Meeting Will be Held at The Hilton Hotel, San Francisco, CA SAN FRANCISCO, CA, May 21, 2024—American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that its Annual Meeting of Shareholders will be held on Tuesday, June 25, 2024, at 9:00 a.m. PT. The Annual Meeting will be an in-person meeting. For those who wish to attend, the...

ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

May 15, 2024

Conference Call on Wednesday, May 15, 2024, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, CA, May 15, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc. On track to ship research use only (RUO) GraftAssureTM transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024. IVD...

American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on Tuesday, June 25, 2024

American Shared Hospital Services Reports First Quarter 2024 Financial Results

May 14, 2024

- Reports Record Backlog of $210 million more than doubling following the acquisition of Rhode Island Radiation Therapy Cancer Centers in May 2024 - - Remains on track with opening new Puebla, Mexico center - -Conference Call Today, May 14th at 4:30 pm ET - SAN FRANCISCO, CA, May 14, 2024—American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

May 14, 2024

Company Achieves Record-Breaking First Quarter Results for 2024, Marking the Launch of BioStem 2.0 Company Reports First Quarter EBITDA of $4.9 Million Project Continued Growth from Sales of AmnioWrap2 ® Financial Results Conference Call and Webcast on Tuesday, May 14, 2024, at 4:30 pm EDT POMPANO BEACH, FLORIDA, May 14, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived...